Executive summary
India’s healthcare system depends daily on medical radioisotopes for diagnostics and cancer therapy. Yet isotope availability remains structurally fragile due to import dependence, centralised production models, and periodic supply disruptions.
This paper examines India-specific demand patterns and outage experiences, and explains why medical isotopes must be treated as critical health infrastructure.
1. India’s medical isotope demand: quiet but massive
India conducts millions of nuclear-medicine procedures annually, with steady growth driven by:
- Rising cancer incidence
- Expanded cardiac diagnostics
- Greater penetration of PET and SPECT imaging
- Public-sector programmes and private hospital expansion
Key demand characteristics:
- High volume, low tolerance for interruption
- Strong urban-rural disparity in access
- Dependence on time-sensitive isotopes such as Tc-99m and therapeutic beta emitters
Unlike drugs, isotope demand cannot be stockpiled. Supply must match usage windows precisely.
2. Import dependence and structural exposure
A significant fraction of India’s medical isotopes or their parent nuclides are imported. This creates exposure to:
- Overseas reactor outages
- Export prioritisation by producing nations
- International transport disruptions
- Customs and regulatory delays
These risks are not theoretical. They have materialised repeatedly.
3. Outage events: what India has already experienced
A. Global reactor shutdowns
Over the past decade, scheduled and unscheduled shutdowns of ageing isotope-producing reactors worldwide have caused:
- Sudden reduction in Mo-99 availability
- Short-notice rationing by suppliers
- Forced rescheduling of diagnostic procedures in India
India, as an importer, absorbs these shocks last and recovers slowest.
B. Pandemic-era transport disruptions
During COVID-19:
- International air-cargo capacity collapsed
- Isotope delivery schedules became unpredictable
- Hospitals reported cancellations and degraded imaging quality
Even when production exists, logistics fragility can cripple availability.
C. Domestic centralisation constraints
India’s indigenous nuclear and isotope ecosystem, anchored around institutions such as Bhabha Atomic Research Centre, has world-class scientific capability. However:
- Production is geographically concentrated
- Scaling for nationwide healthcare demand is non-trivial
- Research reactors and production facilities have competing priorities
Centralised excellence does not automatically translate into distributed healthcare reliability.
4. The hidden cost to hospitals and patients
When isotope supply tightens:
- Hospitals downgrade protocols or delay scans
- Patients travel longer distances
- Diagnostic confidence drops due to lower administered activity
- Treatment-planning timelines slip
These are systemic costs, not isolated inconveniences.
Case vignette: a Tier-2 city hospital
Location: Tier-2 Indian city (population ~2 million)
Facility: Mid-sized tertiary-care hospital with nuclear-medicine department
The hospital runs nuclear-medicine services 3–4 days per week, scheduled around imported Tc-99m-based radiopharmaceuticals.
During a recent supply disruption caused by delayed international logistics:
- The isotope shipment arrived ~36 hours later than planned
- Delivered activity was ~30–35% lower than expected due to decay
- Imaging quality was compromised for heavier patients
- Several scans were deferred
- Two oncology patients were rescheduled for the following week
- One cardiac study was referred to a metro hospital 300+ km away
No regulatory violation occurred. No single actor was at fault. Yet the system failed patients.
The hidden costs did not appear on any invoice: patient travel expenses, lost diagnostic confidence, reduced throughput, permanently expanded scheduling buffers.
Infrastructure insight: the hospital does not require more imported isotope or better email coordination. It requires shorter distance between production and use.
5. Why this is a policy blind spot in India
Medical isotopes fall between silos:
- Nuclear regulation focuses on safety and compliance (AERB)
- Healthcare policy focuses on service delivery
- Industrial policy focuses on manufacturing scale
- Trade policy treats isotopes as specialised imports
No single framework owns end-to-end availability assurance. Shortages are treated as temporary crises. Long-term resilience is under-designed.
6. Infrastructure thinking applied to the Indian context
If isotopes are treated as critical infrastructure:
- Redundancy is justified, not wasteful
- Distributed production near demand centres becomes rational
- Accelerator and neutron-based systems complement reactors
- Regional healthcare equity improves
This mirrors how India already treats power generation, telecommunications, and oil reserves. Healthcare isotopes deserve the same seriousness.
7. Distributed production as a national resilience layer
Distributed isotope production does not replace large research reactors or central expertise. Instead, it:
- Reduces logistics distance
- Dampens global supply shocks
- Supports regional hospitals
- Converts decay losses into usable clinical value
For a country of India’s scale, this is not optional. It is structural prudence.
The pressure is not evenly distributed across the isotope portfolio. Lutetium-177, used in targeted radioligand therapy for prostate cancer and neuroendocrine tumours, is the fastest-growing therapeutic radionuclide globally — with documented supply gaps even in the world’s best-resourced health systems. Several fast-neutron isotopes — Sc-47, Cu-64, Cu-67 — require neutron energies above 1 MeV at clinical grade and are physically inaccessible to thermal reactors. India has essentially no domestic capacity for these. The clinical demand is being created faster than the production base is being built.
Closing note
India does not suffer from a lack of nuclear expertise. It suffers from a classification error.
Medical isotopes are treated as specialised inputs, when in reality they function as foundational healthcare infrastructure.
Correcting this framing unlocks better engineering, better policy, and more reliable care.
The challenge is not capability. It is recognition.